Top

Published in:

01-06-2018 | Original Article

Thromboprophylaxis and the route of administration of chemotherapy in testicular cancer patients in German-speaking countries

Authors: Tim Nestler, Johannes Huber, Adrienne M. Laury, Hendrik Isbarn, Axel Heidenreich, Hans U. Schmelz, Christian G. Ruf

Published in: World Journal of Urology | Issue 6/2018

Abstract

Purpose

Due to the excellent cure rates for testicular cancer (TC), focus has shifted towards decreasing therapy-related morbidities. Thrombosis is a frequent complication of cisplatin chemotherapy. Furthermore, the optimal route of administration for chemotherapy is still under debate. The purpose of this study was to assess the patterns of care concerning dosing and duration of thromboprophylaxis currently utilized in TC patients in German-speaking countries as well as the route of chemotherapy administration.

Methods

A standardized questionnaire was sent to all members of the German TC Study Group (GTCSG) and to all the urological university hospitals in Germany. The questionnaire was also sent to the oncologic clinics at those universities where urologists do not administer chemotherapy.

Results

The response rate was 87% (55/63). Prophylactic anticoagulation with low-molecular-weight heparin (LMWH) was administered in 94% of the clinics. The dosing of LMWH was prophylactic (85%), high prophylactic (adjusted to bodyweight) (7%), or risk adapted (9%). After completion of chemotherapy, anticoagulation was continued in 15 clinics (33%) for 2 to 24 weeks, while the remainder stopped the LMWH upon cessation of chemotherapy. Chemotherapy was administered via central venous access in 59%, peripheral IV in 27%, or both in 14% of the clinics.

Conclusions

Most of the institutions performed some form of thromboprophylaxis, although the modes of application varied by institution type and amongst the urologists and oncologists. Prospective studies are needed to evaluate the incidence, date of occurrence, and risk factors of venous thrombosis during TC chemotherapy to provide a recommendation concerning prophylactic anticoagulation.

Available only for authorised users

Robert Koch-Institut H (2016) Bericht zum Krebsgeschehen in Deutschland 2016. Berlin. https://doi.org/10.17886/rkipubl-2016-014 CrossRef

Nigam M, Aschebrook-Kilfoy B, Shikanov S, Eggener S (2015) Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol 33(5):623–631. https://doi.org/10.1007/s00345-014-1361-y CrossRefPubMed

Ruf CG, Isbarn H, Wagner W, Fisch M, Matthies C, Dieckmann KP (2014) Changes in epidemiologic features of testicular germ cell cancer: age at diagnosis and relative frequency of seminoma are constantly and significantly increasing. Urol Oncol. https://doi.org/10.1016/j.urolonc.2012.12.002 PubMedCrossRef

Einhorn LH, Donohue J (1977) Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87(3):293–298CrossRefPubMed

Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP, Nicolai N, Oldenburg J (2015) Guidelines on testicular cancer: 2015 update. Eur Urol 68(6):1054–1068. https://doi.org/10.1016/j.eururo.2015.07.044 CrossRefPubMed

Fung C, Fossa SD, Milano MT, Sahasrabudhe DM, Peterson DR, Travis LB (2015) Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol 33(28):3105–3115. https://doi.org/10.1200/JCO.2014.60.3654 CrossRefPubMedPubMedCentral

de Haas EC, Zwart N, Meijer C, Nuver J, Boezen HM, Suurmeijer AJ, Hoekstra HJ, van der Steege G, Sleijfer DT, Gietema JA (2008) Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer. J Clin Oncol 26(11):1817–1823. https://doi.org/10.1200/JCO.2007.14.1606 CrossRefPubMed

Boer H, Proost JH, Nuver J, Bunskoek S, Gietema JQ, Geubels BM, Altena R, Zwart N, Oosting SF, Vonk JM, Lefrandt JD, Uges DR, Meijer C, de Vries EG, Gietema JA (2015) Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors. Ann Oncol 26(11):2305–2310. https://doi.org/10.1093/annonc/mdv369 CrossRefPubMedPubMedCentral

Lubberts S, Boer H, Altena R, Meijer C, van Roon AM, Zwart N, Oosting SF, Kamphuisen PW, Nuver J, Smit AJ, Mulder AB, Lefrandt JD, Gietema JA (2016) Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy. Eur J Cancer 63:180–188. https://doi.org/10.1016/j.ejca.2016.05.022 CrossRefPubMed

10.

Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293(6):715–722. https://doi.org/10.1001/jama.293.6.715 CrossRefPubMed

11.

Heidegger I, Porres D, Veek N, Heidenreich A, Pfister D (2017) Predictive factors for developing venous thrombosis during cisplatin-based chemotherapy in testicular cancer. Urol Int 99(1):104–109. https://doi.org/10.1159/000471888 CrossRefPubMed

12.

Bezan A, Posch F, Ploner F, Bauernhofer T, Pichler M, Szkandera J, Hutterer GC, Pummer K, Gary T, Samonigg H, Beyer J, Winder T, Hermanns T, Fankhauser CD, Gerger A, Stotz M (2017) Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. PLoS ONE 12(4):e0176283. https://doi.org/10.1371/journal.pone.0176283 CrossRefPubMedPubMedCentral

13.

Klok FA, van der Hulle T, den Exter PL, Lankeit M, Huisman MV, Konstantinides S (2014) The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. Blood Rev 28(6):221–226. https://doi.org/10.1016/j.blre.2014.07.003 CrossRefPubMed

14.

Pesavento R, Bernardi E, Concolato A, Dalla Valle F, Pagnan A, Prandoni P (2006) Postthrombotic syndrome. Semin Thromb Hemost 32(7):744–751. https://doi.org/10.1055/s-2006-951460 CrossRefPubMed

15.

Encke A, Haas S, Kopp I (2016) The prophylaxis of venous thromboembolism. Dtsch Arztebl Int 113(31–32):532–538. https://doi.org/10.3238/arztebl.2016.0532 PubMedPubMedCentralCrossRef

16.

Draugalis JR, Coons SJ, Plaza CM (2008) Best practices for survey research reports: a synopsis for authors and reviewers. Am J Pharm Educ 72(1):11CrossRefPubMedPubMedCentral

17.

Gizzi M, Oberic L, Massard C, Poterie A, Gwenael LT, Loriot Y, Albiges L, Baciarello G, Michels J, Bossi A, Blanchard P, Escudier B, Fizazi K (2016) Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. Eur J Cancer 69:151–157. https://doi.org/10.1016/j.ejca.2016.10.003 CrossRefPubMed

18.

Honecker F, Koychev D, Luhmann AD, Langer F, Dieckmann KP, Bokemeyer C, Oechsle K (2013) Venous thromboembolic events in germ cell cancer patients undergoing platinum-based chemotherapy. Onkologie 36(11):663–668. https://doi.org/10.1159/000355652 CrossRefPubMed

19.

Piketty AC, Flechon A, Laplanche A, Nouyrigat E, Droz JP, Theodore C, Fizazi K (2005) The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer 93(8):909–914. https://doi.org/10.1038/sj.bjc.6602791 CrossRefPubMedPubMedCentral

20.

Riess H, Pelzer U, Hilbig A, Stieler J, Opitz B, Scholten T, Kauschat-Bruning D, Bramlage P, Dorken B, Oettle H (2008) Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer 8:361. https://doi.org/10.1186/1471-2407-8-361 CrossRefPubMedPubMedCentral

21.

Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, Soff G, Parameswaran R, Hassoun H (2011) High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 29(25):3466–3473. https://doi.org/10.1200/JCO.2011.35.5669 CrossRefPubMed

22.

Solari L, Kronig M, Ihorst G, Drognitz K, Heinz J, Jilg CA, Schultze-Seemann W, Engelhardt M, Waller CF (2016) High rates of thromboembolic events in patients with germ cell cancer undergoing cisplatin-based polychemotherapy. Urol Int 96(4):399–405. https://doi.org/10.1159/000445126 CrossRefPubMed

23.

Phan M, John S, Casanegra AI, Rathbun S, Mansfield A, Stoner JA, Tafur AJ (2014) Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. J Thromb Thrombolysis 38(2):241–249. https://doi.org/10.1007/s11239-013-1014-9 CrossRefPubMedPubMedCentral

24.

Lemmers NW, Gels ME, Sleijfer DT, Plukker JT, van der Graaf WT, de Langen ZJ, Droste JH, Koops HS, Hoekstra HJ (1996) Complications of venous access ports in 132 patients with disseminated testicular cancer treated with polychemotherapy. J Clin Oncol 14(11):2916–2922CrossRefPubMed

25.

Worst T, Sautter L, John A, Weiss C, Hacker A, Heinzelbecker J (2016) Cisplatin-based chemotherapy for testicular germ cell tumors: complication rates of peripheral versus central venous administration. Urol Int 96(2):177–182. https://doi.org/10.1159/000442003 CrossRefPubMed

26.

Lee AY, Kamphuisen PW (2012) Epidemiology and prevention of catheter-related thrombosis in patients with cancer. J Thromb Haemost 10(8):1491–1499. https://doi.org/10.1111/j.1538-7836.2012.04817.x CrossRefPubMed

27.

Nayeemuddin M, Pherwani AD, Asquith JR (2013) Imaging and management of complications of central venous catheters. Clin Radiol 68(5):529–544. https://doi.org/10.1016/j.crad.2012.10.013 CrossRefPubMed

28.

Yoshida Y, Hoshino S, Aisu N, Naito M, Tanimura S, Mogi A, Tanaka T, Hirata K, Tamura K, Yamashita Y (2015) Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients. Int J Clin Oncol 20(2):332–337. https://doi.org/10.1007/s10147-014-0703-5 CrossRefPubMed

29.

de Wit M, Ortner P, Lipp HP, Sehouli J, Untch M, Ruhnke M, Mayer-Steinacker R, Bokemeyer C, Jordan K (2013) Management of cytotoxic extravasation - ASORS expert opinion for diagnosis, prevention and treatment. Onkologie 36(3):127–135. https://doi.org/10.1159/000348524 CrossRefPubMed

Title: Thromboprophylaxis and the route of administration of chemotherapy in testicular cancer patients in German-speaking countries
Authors: Tim Nestler
Johannes Huber
Adrienne M. Laury
Hendrik Isbarn
Axel Heidenreich
Hans U. Schmelz
Christian G. Ruf
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 6/2018
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2222-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Thromboprophylaxis and the route of administration of chemotherapy in testicular cancer patients in German-speaking countries

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

Long-term oncological outcomes after robotic partial nephrectomy for renal cell carcinoma: a prospective multicentre study

Comparison of super-mini PCNL (SMP) versus Miniperc for stones larger than 2 cm: a propensity score-matching study

Antimicrobial lubricant reduces rectal bacteria at transrectal prostate biopsy: results from a prospective randomized trial

Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study

Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial

Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation